AGM Details

The 27th Annual General Meeting will be held on Thursday, September 17, 2026, at 10:30 A.M. IST through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The proceedings will be deemed conducted at the Registered Office of the Company at Plot No. DS-7, IKP Knowledge Park, Turkapally (V), Shameerpet Mandal, Medchal-Malkajgiri (Dist), Hyderabad -500078, Telangana, India.

Ordinary Business Items

1. To receive, consider and adopt:

  • The Audited Standalone Financial Statements for the year ended 31 March 2026, with reports of Board of Directors and auditors
  • The Audited Consolidated Financial Statements for the year ended 31 March 2026 with auditor's report

2. To appoint a director in place of Mr. Krishnamraju Kanumuri (DIN: 00064614), who retires by rotation and being eligible, offers himself for re-appointment

Director Re-appointment Details

Mr. Krishnamraju Kanumuri (DIN: 00064614)

  • Date of Birth: 10th February 1970 (Age: 56 years as on March 31, 2026)
  • First appointed as director on 1 May 2004, continued till 1 August 2008
  • Appointed as Managing Director on 1 October 2010
  • Designated as Managing Director and CEO w.e.f. 1 September 2016
  • Qualification: Bachelor's degree in chemical engineering from Mangalore University and MBA in Finance from University of Kansas, USA
  • Category: Managing Director and CEO (Executive Director under Promoter category)
  • Remuneration paid for FY 2025-26: ₹13,07,65,004
  • Relationship: Son of Dr. Ranga Raju Kanumuri (Whole Time Director and Chairman)
  • Equity holding: 30,08,400 Equity Shares of ₹1/- each as on 31.03.2026

Director's Professional Background

With over 25 years of experience, Mr. Krishnamraju Kanumuri has been instrumental in transforming Sai Life Sciences into a leading global CRDMO. He joined in 2004 as Vice President, Business Development and has driven the company's evolution from a domestic service provider to a global partner. In 2019, he spearheaded strategic investments in global R&D capabilities including centers in Boston and Manchester.

Under his leadership, the company delivered significant growth:

  • Consolidated revenue increased from ₹870 Cr. in FY2022 to ₹2,242 Cr. in FY2026
  • EBITDA rose from ₹131 Cr. to ₹661 Cr.
  • PAT increased from ₹6 Cr. to ₹349 Cr.

The company completed its IPO in December 2024 under his leadership.

Directorships Held (as on March 31, 2026)

1. Sai Life Pharma Private Limited (100% subsidiary) as Managing Director (Promoter)

2. Sai Life Sciences Inc, USA (100% subsidiary)

3. Sai Life Sciences, GmbH (100% subsidiary)

4. South India Research Institute Private Limited as Non-Executive Director

All directorships are without remuneration.

Committee Memberships

  • Stakeholders Relationship Committee - Member
  • Risk Management Committee - Member
  • Corporate Social Responsibility and Sustainability Committee - Member
  • Attended all Board Meetings during FY 2025-26

Voting and Participation Details

Cut-off Date: September 10, 2026 (shareholders as of this date are eligible to vote)

Remote e-Voting Period: September 14, 2026 (9:00 a.m. IST) to September 16, 2026 (5:00 p.m. IST)

Voting Service Provider: KFin Technologies Limited (RTA)

Virtual Meeting Access: Members can join 30 minutes before commencement at https://emeetings.kfintech.com using e-voting credentials

Document Availability

The Notice and Annual Report for FY 2025-26 are available on:

  • Company website: www.sailife.com
  • BSE website: www.bseindia.com
  • NSE website: www.nseindia.com
  • KFinTech website: https://evoting.kfintech.com

Audited Accounts of subsidiaries are available on the company's website.

Key Contacts

RTA: KFin Technologies Limited, Selenium Building, Tower-B, Plot No. 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana - 500032, Email: einward.ris@kfintech.com, Toll Free: 1800 309 4001